WHO ICTRP trial
Novel treatment for Recurrent High Grade Brain tumors
CTRI/2025/03/082390 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2025/03/082390 |
|---|---|
| Public title | Novel treatment for Recurrent High Grade Brain tumors |
| Scientific title | Pilot Study for intra-tumoral administration of L- 2,4- Diamino-N-Butyric Acid Dihydrochloride (DAB) and Prazosin in 10 recurrent glioblastoma patients - NIL |
| Primary sponsor | St Johns Medical College Hospital |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: C718- Malignant neoplasm of overlappingsites of brain Health Condition 2: O- Medical and Surgical |
| Interventions | Intervention1: 2,4 Diamino Butyricacid Dihydrochloride(DAB) and Prazosin: A novel treatment for recurrent glioblastoma that involves intra-tumoral administration of a a proprietary mixture of two drugs. Following Surgical tumour resection a… |
| Registration date | Mar 17, 2025 |
| Target size | 10 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: